These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9010229)
1. The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding. Broome MA; Hunter T Oncogene; 1997 Jan; 14(1):17-34. PubMed ID: 9010229 [TBL] [Abstract][Full Text] [Related]
2. Molecular interactions of the Src homology 2 domain protein Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 domain proteins. Karlsson T; Songyang Z; Landgren E; Lavergne C; Di Fiore PP; Anafi M; Pawson T; Cantley LC; Claesson-Welsh L; Welsh M Oncogene; 1995 Apr; 10(8):1475-83. PubMed ID: 7537362 [TBL] [Abstract][Full Text] [Related]
3. Association of Fyn with the activated platelet-derived growth factor receptor: requirements for binding and phosphorylation. Twamley GM; Kypta RM; Hall B; Courtneidge SA Oncogene; 1992 Oct; 7(10):1893-901. PubMed ID: 1408131 [TBL] [Abstract][Full Text] [Related]
4. Crk protein binds to PDGF receptor and insulin receptor substrate-1 with different modulating effects on PDGF- and insulin-dependent signaling pathways. Sorokin A; Reed E; Nnkemere N; Dulin NO; Schlessinger J Oncogene; 1998 May; 16(19):2425-34. PubMed ID: 9627109 [TBL] [Abstract][Full Text] [Related]
5. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Sachsenmaier C; Sadowski HB; Cooper JA Oncogene; 1999 Jun; 18(24):3583-92. PubMed ID: 10380880 [TBL] [Abstract][Full Text] [Related]
6. Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins. Yokote K; Hellman U; Ekman S; Saito Y; Rönnstrand L; Saito Y; Heldin CH; Mori S Oncogene; 1998 Mar; 16(10):1229-39. PubMed ID: 9546424 [TBL] [Abstract][Full Text] [Related]
7. PDGF-induced phosphorylation of Tyr28 in the N-terminus of Fyn affects Fyn activation. Hansen K; Alonso G; Courtneidge SA; Rönnstrand L; Heldin CH Biochem Biophys Res Commun; 1997 Dec; 241(2):355-62. PubMed ID: 9425276 [TBL] [Abstract][Full Text] [Related]
8. RACK1: a novel substrate for the Src protein-tyrosine kinase. Chang BY; Harte RA; Cartwright CA Oncogene; 2002 Oct; 21(50):7619-29. PubMed ID: 12400005 [TBL] [Abstract][Full Text] [Related]
9. Receptor association and tyrosine phosphorylation of S6 kinases. Rebholz H; Panasyuk G; Fenton T; Nemazanyy I; Valovka T; Flajolet M; Ronnstrand L; Stephens L; West A; Gout IT FEBS J; 2006 May; 273(9):2023-36. PubMed ID: 16640565 [TBL] [Abstract][Full Text] [Related]
10. Regulation of the cellular src protein tyrosine kinase: interactions of the carboxyl terminal sequences residing between the kinase domain and tyrosine-527. Cobb BS; Parsons JT Oncogene; 1993 Nov; 8(11):2897-903. PubMed ID: 7692368 [TBL] [Abstract][Full Text] [Related]
11. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Moarefi I; LaFevre-Bernt M; Sicheri F; Huse M; Lee CH; Kuriyan J; Miller WT Nature; 1997 Feb; 385(6617):650-3. PubMed ID: 9024665 [TBL] [Abstract][Full Text] [Related]
12. Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. Broome MA; Hunter T J Biol Chem; 1996 Jul; 271(28):16798-806. PubMed ID: 8663329 [TBL] [Abstract][Full Text] [Related]